NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01
Change in Registrant’s Certifying Accountant
(a) Dismissal of Independent Registered Public Accounting Firm.
On February27, 2019, the Audit Committee of the Board of Directors of NeoGenomics, Inc. (the “Company”) dismissed Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm, effective following the issuance of the Company’s Annual Report on Form10‑K for the period ended December 31, 2018.
Crowe’s reports on the Company’s financial statements for the fiscalyears ended December31, 2018 and 2017 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the Company’s two most recent fiscalyears ended December31, 2018 and 2017 and the subsequent interim period through February27, 2019, there were:
(i) No “disagreements” (within the meaning of Item304(a)of Regulation S-K) with Crowe on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Crowe, would have caused it to make reference to the subject matter of the disagreements in its reports on the consolidated financial statements of the Company; and
(ii) No “reportable events” (as such term is defined in Item304(a)(1)(v)of Regulation S-K).
The Company has provided Crowe with a copy of this Form8‑K prior to its filing with the U.S. Securities and Exchange Commission (“SEC”) and requested Crowe to furnish to the Company a letter addressed to the SEC stating that it agrees with the statements made above. A copy of Crowe’s letter dated March05, 2019 is attached as Exhibit16.1 to this Form8‑K.
(b) Engagement of New Independent Registered Public Accounting Firm.
On February 27, 2019, the Audit Committee approved the selection of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
During the two most recent fiscal years ended December 31, 2018 and 2017, and the subsequent interim periods through February 27, 2019, neither the Company nor anyone on its behalf consulted Deloitte regarding either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements or any matter that was either the subject of a “disagreement” (within the meaning of Item304(a)of Regulation S-K) or a “reportable event” (as such term is defined in Item304(a)(1)(v)of Regulation S-K).
|
Item 4.01. |
Financial Statements and Exhibits. |
(d) Exhibits
Exhibit Index
NEOGENOMICS INC Exhibit
EX-16.1 2 exhibit161neogenomicsc.htm EXHIBIT 16.1 Exhibit Exhibit 16.1March 5,…
To view the full exhibit click here
About NEOGENOMICS, INC. (NASDAQ:NEO)
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.
